Stock BLRX BIOLINERX LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News BioLineRx Ltd. Nasdaq

Equities

BLRX

US09071M2052

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-14 EDT 		5-day change 1st Jan Change
0.6449 USD +3.68% Intraday chart for BioLineRx Ltd. -5.52% -58.92%
04-17 BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting CI
04-10 BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
PU
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
CI
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
PR
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
CI
BioLineRx Announces $6 Million Registered Direct Offering
AQ
BioLineRx Shares Fall After $6 Million Registered Direct Offering
MT
BioLineRx : Form 20-F/A (Amendment No. 1
PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
AQ
BioLineRx : Annual Report on Form 20-F FOR 2023
PU
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024
BioLineRx : Report of Periodic or Interim Report
PU
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
PU
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production
CI
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer
CI
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?
CI
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BLRX Stock
  4. BLRX Stock
  5. News BioLineRx Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW